The antibody replacement technology was co-developed by the California Institute of Technology.
US-based diagnostic and therapeutic technology developer Indi Molecular has received $11.5m in a series A round co-led by M Ventures, the corporate venturing unit of Germany-headquartered pharmaceutical firm Merck Group.
M Ventures, which is known as Merck Ventures outside the US and Canada, co-led the round with Legend Capital, the private equity and venture capital firm sponsored by conglomerate Legend Holdings, and real estate and investment firm Sabey Corporation.
The round was filled out by existing investors including venture capital…
